Neutralizing Antibodies to Interferon β-1b are not Associated with Disease Worsening in Multiple Sclerosis
Authors:
- 1 March 2007
- journal article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 35 (2) , 173-187
Abstract
The clinical impact of neutralizing antibodies (NAbs) on interferon beta (IFNβ) efficacy was studied in three large patient cohorts comprising 6698 multiple sclerosis (MS) patients receiving IFNβ-1b across North America, Europe, and Australia. In North America and Europe, NAb testing was generally undertaken because of a poor clinical response; in Australia, it was mandatory for every patient. Of the 6697 patients tested, 28.9% had at least one NAb titre ≥ 20 neutralizing units (NU)/ml, 14.4% had NAb titres ≥ 100 NU/ml and 7.7% had NAb titres ≥ 400 NU/ml. The NAb-positive rate of 37.0% in Australia was significantly greater than those in North America (21.3%) and Europe (27.6%), and this was observed at every NAb titre level. Our results suggest that NAbs are not responsible for poor clinical responses and that NAb status is of little clinical value. These findings will need to be confirmed in a large independent study.Keywords
This publication has 39 references indexed in Scilit:
- Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohortJournal of Immunological Methods, 2006
- Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trialJournal of the Neurological Sciences, 2005
- Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosisThe Lancet Neurology, 2005
- Efecto a largo plazo de los anticuerpos neutralizantes de interferón beta-1 b en pacientes con esclerosis múltipleMedicina Clinica, 2005
- The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction UnitJournal of Interferon & Cytokine Research, 2001
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparationsImmunopharmacology, 2000
- A Novel Sensitive and Selective Bioassay for Human Type I InterferonsJournal of Interferon & Cytokine Research, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interfer beta augments supperssor cell function in multiple sclerosisAnnals of Neurology, 1990